Announcements Trials

Browse Landscape

Phase

Phase NA 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 66 Carcinoma, Renal Cell 38 Liver Neoplasms 20 Neoplasm Metastasis 17 Carcinoma, Non-Small-Cell Lung 16 Neoplasms 15 Breast Neoplasms 15 Melanoma 13 Thyroid Neoplasms 10 Leukemia, Myeloid, Acute 10 Sarcoma 9 Lung Neoplasms 8 Kidney Neoplasms 8 Prostatic Neoplasms 7 Ovarian Neoplasms 7 Urinary Bladder Neoplasms 6 Pancreatic Neoplasms 6 Glioblastoma 6 Brain Neoplasms 6 Colorectal Neoplasms 5 Carcinoma, Medullary 5 Thyroid Carcinoma, Anaplastic 4 Stomach Neoplasms 4 Rectal Neoplasms 4 Gliosarcoma 4 Gallbladder Neoplasms 4 Colonic Neoplasms 4 Breast Neoplasms, Male 4 Thyroid Diseases 3 Thyroid Cancer, Papillary 3

Interventions

nimotuzumab 1 lenvatinib 1 atezolizumab 1 Sorafenib 1 Radiotherapy 1 Radiosurgery 1 Immune Checkpoint Inhibitors 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × HCC × Sorafenib × Clear all

NCT05873244 2025-03-21

CXD101 in Immunotherapy-related Liver Cancer

Chinese University of Hong Kong

Phase 2 Recruiting

HCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡